

Saudi Arabia Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region, Competition, Forecast & Opportunities, 2020-2030F

<https://marketpublishers.com/r/SBBA67283EFDEN.html>

Date: April 2025

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: SBBA67283EFDEN

Abstracts

Market Overview

The Saudi Arabia Human Insulin Market was valued at USD 0.32 Billion in 2024 and is projected to reach USD 0.35 Billion by 2030, growing at a CAGR of 1.70% during the forecast period. Human insulin, a peptide hormone produced by the pancreas, is essential for regulating blood glucose levels by facilitating the uptake of glucose into cells for energy. Its use is critical in managing diabetes, particularly for those with Type 1 diabetes and advanced Type 2 cases. As Saudi Arabia's population ages and urbanization continues, lifestyle-related factors such as obesity and sedentary habits are contributing to rising diabetes rates, thus fueling demand for insulin. Increased awareness, healthcare provider guidance, and improvements in insulin delivery technologies further support market growth. In addition, expanded insurance coverage and reimbursement for insulin therapies are reducing financial barriers for patients, encouraging greater adoption. This steady demand, driven by demographic trends and

healthcare system evolution, is shaping the growth trajectory of the human insulin market in the Kingdom.

Key Market Drivers

Rising Prevalence of Diabetes

The growing incidence of diabetes is a key factor driving demand in the Saudi Arabia Human Insulin Market. With an estimated 18.7% of adults aged 20 to 79 affected, diabetes has become a major public health issue. The surge in Type 2 Diabetes Mellitus (T2DM) is especially concerning, having risen dramatically from 8.5% in 1992 to 39.5% by 2022. This increase is largely attributed to rising obesity rates and unhealthy lifestyle habits. Type 1 diabetes patients depend entirely on insulin therapy, while many T2DM patients eventually require insulin as their condition progresses. The younger onset age of diabetes in Saudi Arabia extends the treatment duration and insulin consumption per patient. These factors collectively drive sustained market growth, creating a significant demand for human insulin products across the country.

Key Market Challenges

Quality and Safety

Maintaining the quality and safety of human insulin products presents a notable challenge in Saudi Arabia's market. Compliance with regulatory standards set by authorities such as the Saudi Food and Drug Authority (SFDA) is essential, yet challenging. The threat of counterfeit or substandard insulin poses significant risks to patient health, requiring rigorous oversight from manufacturers, regulators, and distributors. Proper handling and storage are critical, as temperature variations and mishandling can compromise insulin efficacy. Additionally, the complex supply chain increases the risk of contamination or tampering. Product recalls due to safety issues can damage public trust and disrupt treatment for patients. Ensuring consistent product quality demands strict manufacturing controls and active monitoring of adverse events to identify and address safety concerns promptly.

Key Market Trends

Biopharmaceutical Developments

Biopharmaceutical innovation is transforming the Saudi Arabia Human Insulin Market,

with companies increasingly utilizing recombinant DNA technologies to produce insulin. These biotechnologically developed insulin products closely mimic naturally occurring human insulin and offer higher purity, better glycemic control, and fewer side effects compared to animal-derived alternatives. Long-acting analogs such as insulin glargine and degludec provide extended basal insulin coverage, while rapid-acting analogs like insulin lispro and aspart support efficient post-meal glucose control. Personalized insulin therapies and biosimilar developments are also gaining momentum, providing cost-effective alternatives without compromising safety or efficacy. These advancements are expanding treatment options and supporting more tailored, flexible diabetes management for patients across the Kingdom.

Key Market Players

Novo Nordisk Saudi Arabia

Sanofi Saudi Arabia

Baxter International Saudi Arabia

B Braun Saudi Arabia

Eli Lilly and Company Saudi Arabia

Pfizer Saudi Arabia

Report Scope:

In this report, the Saudi Arabia Human Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Saudi Arabia Human Insulin Market, By Indication:

Type I Diabetes

Type II Diabetes

Saudi Arabia Human Insulin Market, By Route of Administration:

Subcutaneous

Nasal

Intravenous

Transdermal

Oral

Others

Saudi Arabia Human Insulin Market, By Type:

Basal

Bolus

Pre-mixed

Biosimilar

Traditional

Saudi Arabia Human Insulin Market, By Onset Time:

Rapid Acting

Short-Acting

Intermediate Acting

Long Acting

Ultra-long Acting

Pre-Mixed

Inhaled

Saudi Arabia Human Insulin Market, By Products:

Insulin Pens

Insulin Pumps

Infusion System

Injection

Saudi Arabia Human Insulin Market, By Region:

Eastern

Western

Northern & Central

Southern

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Saudi Arabia Human Insulin Market.

Available Customizations:

Saudi Arabia Human Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. SAUDI ARABIA HUMAN INSULIN MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Indication (Type I Diabetes, Type II Diabetes)
 - 5.2.2. By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
 - 5.2.3. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)

5.2.4. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)

5.2.5. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)

5.2.6. By Region

5.2.7. By Company (2024)

5.3. Market Map

6. NORTHERN & CENTRAL SAUDI ARABIA HUMAN INSULIN MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Indication

6.2.2. By Route of Administration

6.2.3. By Type

6.2.4. By Onset Time

6.2.5. By Products

7. EASTERN SAUDI ARABIA HUMAN INSULIN MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Indication

7.2.2. By Route of Administration

7.2.3. By Type

7.2.4. By Onset Time

7.2.5. By Products

8. WESTERN SAUDI ARABIA HUMAN INSULIN MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Indication

8.2.2. By Route of Administration

8.2.3. By Type

8.2.4. By Onset Time

8.2.5. By Products

9. SOUTHERN SAUDI ARABIA HUMAN INSULIN MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Indication

9.2.2. By Route of Administration

9.2.3. By Type

9.2.4. By Onset Time

9.2.5. By Products

10. MARKET DYNAMICS

10.1. Drivers

10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

11.1. Recent Developments

11.2. Product Launches

11.3. Mergers & Acquisitions

12. SAUDI ARABIA HUMAN INSULIN MARKET: SWOT ANALYSIS

13. POLICY & REGULATORY LANDSCAPES

14. SAUDI ARABIA ECONOMIC PROFILE

15. COMPETITIVE LANDSCAPE

15.1. Novo Nordisk Saudi Arabia

15.1.1. Business Overview

15.1.2. Product & Service Offerings

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. Financials (If Listed)

15.1.6. SWOT Analysis

15.2. Sanofi Saudi Arabia

- 15.3. Baxter International Saudi Arabia
- 15.4. B Braun Saudi Arabia
- 15.5. Eli Lilly, and Company Saudi Arabia
- 15.6. Pfizer Saudi Arabia

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Saudi Arabia Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region, Competition, Forecast & Opportunities, 2020-2030F

Product link: <https://marketpublishers.com/r/SBBA67283EFDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBBA67283EFDEN.html>